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Abstract: The oldest old population (.85 years of age) represents the faster growing segment 
of the elderly in developed countries. Cardioembolic infarction (CI) accounts for 14%–30% of 
all cerebral infarcts and is the most severe ischemic stroke subtype with the highest in-hospital 
mortality. Also, CI is associated with a low frequency of symptom-free patients at hospital dis-
charge and presents a non-negligible risk of early embolic recurrence. Moreover, cardioembolic 
stroke is the acute cerebrovascular event most commonly found in very old subjects. However, 
some clinical aspects of the natural course of the disease in very old patients are still poorly 
defined. The present report presents an updated review of relevant aspects of CI related to clinical 
manifestations, biological characteristics, prognostic implications, and treatment strategies, which 
may contribute to improving the quality of care and outcome of acute cardioembolic stroke in 
very old patients. The most relevant aspects of CI are discussed based on the data published in 
the literature and the authors’ experience in the management of stroke patients, collected from 
the hospital-based “Sagrat Cor Hospital of Barcelona Stroke Registry”. The following aspects 
are commented on: epidemiologic data and risk factors, clinical characteristics, cardiac workup 
studies, special cardioembolic clinical features, outcome, thrombolytic therapy, antithrombotic 
treatment, and indications for future research lines. Cardioembolic stroke is an important topic 
in the frontier between cardiology and vascular neurology. The impact of CI on the patients’ 
health and quality of life, health care systems, and society in general merits an in-depth review 
of current clinical issues, advances, and controversies.
Keywords: cardioembolic infarction, epidemiology, risk factors, secular trends, stroke registry, 
very old patients
Introduction
The importance of studies on acute cerebrovascular events in older stroke victims is 
growing because of the changes in the age structure of Western populations.1–3 The 
oldest old (85 years or older) represents the faster growing segment of the elderly in 
developed countries.4 In very old patients, cardioembolic stroke is the ischemic stroke 
subtype that occurs more frequently.5 Although there are no absolute criteria for the 
diagnosis of cardioembolic infarction (CI), the following characteristics are required: 
1) compatible neurovascular clinical picture, 2) recognition of an emboligenous heart 
disease, and 3) exclusion of carotid and/or cerebral atherosclerosis as main causes of 
ischemic stroke.6,7
There are few studies on acute ischemic stroke in very old subjects, and little infor-
mation has been published in relation to the cardiovascular risk factors profile for CI in 
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and support, and a high economic burden. Currently, one 
third of all the patients with first-ever acute ischemic stroke 
are .85 years old.2,3,9 As life expectancy continues to rise, 
elderly subjects eventually will constitute the majority of 
stroke victims.4 Acute ischemic stroke in very old patients is 
rapidly becoming a major public health issue. In addition, it 
has been shown that older stroke patients are particularly at 
risk of receiving suboptimal care, with brain neuroimaging 
studies and other diagnostic tools used less frequently than 
in younger patients.10 Additionally, sufficient rehabilitation 
time for older fragile comorbid stroke patients to help their 
recovery is still an unmet need in many rehabilitation wards 
and nursing homes.
In the oldest old population, age 85 and over is an arbitrary 
cutoff age limit for exclusion of stroke patients from clinical 
trials. Elderly patients are often excluded from clinical trials 
studying recombinant tissue plasminogen activator (rtPA) or 
anticoagulation in presumed cardioembolic ischemic stroke. 
Studies that have focused on very old patients suggest that 
very old stroke patients have higher in-hospital mortality 
rates, longer lengths of hospital stay, and receive lesser 
aggressive care than younger patients.10–14 Because of all these 
considerations, diagnosis and management of CI continue 
to be a current challenge for physicians, nurses, physical 
therapists, policy makers, and the society in general.
Clinical characteristics
Cardioembolic cerebral infarction accounts for 18%–25% of 
all cerebral infarctions15–17 and is the ischemic stroke subtype 
most commonly found in very old patients (.85 years of 
age).5,18 In 2,990 patients included in the “Sagrat Cor Hospital 
of Barcelona Stroke Registry” between 1986 and 2004, CI in 
very old patients (mean age 88.5 years) accounted for 28.4% 
of first-ever strokes followed by atherothrombotic infarcts 
(21%) and lacunar infarctions (14.2%), whereas in patients 
younger than 85 years (mean age 70.9 years), lacunar infarc-
tion (20.1%) and atherothrombotic infarcts (18.4%) were 
more frequent than CI (17.5%). This may be explained by 
the fact that the most common emboligenous cardiopathy – 
atrial fibrillation – is more prevalent in the subgroup of very 
old ischemic stroke patients (43.2%) as compared with other 
age subgroups (34.3% in the 75–84-year age group, 23.1% 
in the 65–74-year age group, and 9.8% in the ,65-year age 
group).19,20 It should be noted that in the oldest old patients, 
atrial fibrillation is the second vascular risk factor after 
hypertension, which is in contrast to ages ,65 years and 
65–74 years, during which hypertension, diabetes mellitus, 
and dyslipidemia are the most common risk factors.20
Cardioembolic stroke is a severe condition due to the 
large size of the infarction, with a high in-hospital mortality 
rate (6%–27%) and significant neurological dysfunction; 
also, the risk of spontaneous infarct recurrence ranges 
between 1% and 10%.21–23 Histopathological examination 
of the lesion area usually reveals a hemorrhagic cerebral 
infarction (Figure 1).
Salient clinical manifestations of CI (Table 1) include 
sudden onset of neurological deficit, maximum focal neuro-
logical dysfunction at the onset of clinical symptoms, stroke 
onset while awake, speech disturbances, and the presence of a 
non-lacunar clinical syndrome.24 Early differential diagnosis 
of CI should be mainly established with atherothrombotic 
infarctions, and sometimes, this differential diagnosis can be 
difficult on the basis of clinical symptoms alone.20 However, 
in a comparative clinical study, it was found that sudden 
onset of neurological deficit and heart rhythm disturbance 
were independent predictive variables of cardioembolism, 
whereas hypertension, diabetes, dyslipidemia, and chronic 
obstructive pulmonary disease (COPD) were significantly 
related to atherothrombotic infarction.20 Also, atrial fibril-
lation, heart valve disease, and ischemic heart disease are 
characteristic cardiovascular risk factors for CI, in contrast 
Figure 1 Pathological specimen showing a hemorrhagic cerebral infarction of 
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Current perspectives on cardioembolic ischemic stroke
to the profile of atherothrombotic stroke characterized by the 
presence of peripheral vascular disease, diabetes, previous 
transient ischemic attack or cerebral ischemia, as well as 
concomitant ischemic heart disease.20,25
The commonest high-risk cardioembolic conditions are 
atrial fibrillation, recent myocardial infarction, mechani-
cal prosthetic valve, dilated myocardiopathy, and mitral 
rheumatic stenosis.26–28 Other types of heart diseases associ-
ated with a high risk of embolism are atrial or ventricular 
thrombi, atrial myxoma and cardiac tumors, infectious/
marantic endocarditis, complex aortic arch atheroma, 
and dilated myocardiopathy with ventricular ejection 
fraction ,35%.29
Diagnostic studies
In the last decade, the diagnosis of CI was mainly a 
“presumed” diagnosis based on clinical features and elec-
trocardiography findings. However, clinical diagnosis of CI 
has recently shown a substantial advance in relation to the 
use of echocardiography in routine clinical practice, 24-hour 
Holter monitoring, and diffusion magnetic resonance imag-
ing, allowing a noninvasive diagnosis of potentially embo-
ligenous structural heart diseases, detection of clinically 
silent paroxysmal heart rhythm disorders, or acute multiple 
simultaneous cerebral infarctions, which are characteristics 
of the embolic phenomena.30–32 Also, recent development of 
biological markers related to cerebral cardioembolism, such 
as high serum levels of brain natriuretic peptide of D-dimer, is 
useful to increase the sensitivity of the diagnosis of embolic 
etiology of the brain infarction in those cases of cerebral 
ischemia of undetermined or mixed etiology.33,34
In a comparative study of 575 patients with CI, col-
lected from the “Sagrat Cor Hospital of Barcelona Stroke 
Registry” over a period of 19 years, the percentage of 
patients in whom echocardiography was used increased from 
39.7% in 1986–1992 to 66.9% in 1993–1998 and 73.9% in 
1999–2004.18 The use of echocardiography also increased 
notably in very old patients (16% in 1986–1992, 27.3% in 
1993–1998, 38.2% in 1999–2004).
Outcome
early mortality
Cardioembolic stroke is the subtype of cerebral infarction 
with the highest in-hospital mortality.1,35,36 In our experience, 
early mortality rate due to CI prior to the use of thrombolytic 
therapy was 21.9%, similar to that reported by Caplan et al,37 
as compared to 8.2% in the remaining non-cardioembolic 
strokes, with a frequency of 0.8% in lacunar infarcts and 
21.7% in atherothrombotic stroke.38
In patients with cerebral infarction, in-hospital mortality 
rates were 30%, 22%, and 18% for patients with congestive 
heart failure, atrial fibrillation, and COPD, respectively. In 
the subgroup of cardioembolic stroke, risk factors inde-
pendently related with in-hospital death were peripheral 
vascular disease, previous cerebral infarction, and congestive 
heart failure. In a stepwise multivariate analysis, in which 
demographic variables, cardiovascular risk factors, clinical 
features, and neuroimaging findings were included, decreased 
consciousness, limb weakness, congestive heart failure, male 
sex, and age were statistically significant variables indepen-
dently associated with cardioembolic stroke. Age was an 
independent factor associated with in-hospital mortality. In 
addition to these variables, early recurrent embolism was 
also selected.38
Age is an independent predictive factor associated with 
in-hospital mortality in stroke patients.1,2 In a comparison 
between patients aged $85 years and those aged ,85 years, 
advanced age was a predictive factor for early mortality in 
patients with stroke in general (27% vs 13.5%).19 In patients 
with CI, in-hospital death is also more frequent in very old 
patients (25% vs 11.5%).38
A summary of demographic variables, cerebrovascular 
risk factors, neuroimaging findings, and outcome of first-
ever stroke patients according to age (#84 vs $85 years), 
collected from the “Sagrat Cor Hospital of Barcelona Stroke 
Registry” for the period 1986–2004, is shown in Table 2.
Cardioembolic recurrence
The risk of early stroke recurrence in cerebral infarcts 
ranges between 1% and 10%. In the Cerebral Embolism 
Task Force, it was estimated that 12% of patients with car-
dioembolic stroke would develop a second embolism within 
the first 2 weeks after the initial event.39 In our experience, 
early embolic recurrence was documented in 24 out of 347 
consecutive patients with CI (6.9% of cases).40 Recurrence 
Table 1 Clinical characteristics of cardioembolic infarction
Sudden onset of focal neurological deficit
Maximum focal neurological dysfunction at onset of clinical symptoms
Stroke onset while awake
Onset after a valsalva maneuver (paradoxical embolism)
Presence of a non-lacunar clinical syndrome
wernicke aphasia
isolated aphasia
Spectacular shrinking deficit syndrome
Concomitant peripheral vascular embolism
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occurred within the first 7 days in 12 patients (50%). The 
mean time for recurrence of cardioembolism was 12 days. 
In other studies, cardioembolic recurrence at 30 days was 
observed in five (6.1%) out of 81 patients with CI and non-
valvular atrial fibrillation in the study of Yamanouchi et al,41 
in 6% of patients with cerebral infarctions in the study of 
Sacco et al,42 in 3.3% in the Stroke Data Bank,43 and in 4.4% 
in the Lausanne Stroke Registry.44
Risk factors for stroke recurrence are poorly known. In 
our experience, alcohol abuse, hypertension with valve heart 
disease and atrial fibrillation, nausea and vomiting, and pre-
vious cerebral infarction were significantly associated with 
stroke recurrence.40 In addition to these four variables, cardiac 
events (tachyarrhythmia, heart failure, or acute myocardial 
infarction that occurred as medical complication during the 
patient’s hospital stay) were selected in the multivariate model 
based on clinical, neuroimaging, and outcome variables.40 
However, neither age nor advanced age was per se an inde-
pendent risk factor for cardioembolic recurrence.
Atrial fibrillation as a prognostic  
factor in cardioembolic and 
atherothrombotic infarcts
Atrial fibrillation is the most common heart disease in dif-
ferent clinical series of patients with CI in industrialized 
countries.45–48 Atrial fibrillation can also be present in athero-
thrombotic infarctions, not as an emboligenous etiology but 
as a marker of other conditions that lead to ischemic stroke, 
such as atherosclerosis. Accordingly, it may be considered as 
an epiphenomenon or another manifestation of atheroscle-
rotic disease. Therefore, not all cases of cerebral infarctions in 
patients with atrial fibrillation have a cardioembolic origin.49 
In a study of our group, atrial fibrillation was diagnosed 
in 16.5% of patients with thrombotic occlusion or arterial 
stenosis .70%, which were presumably responsible for the 
cerebral infarct.20
In patients with CI, in-hospital mortality rate was 31.6% 
in patients with atrial fibrillation and 14.8% in those without 
atrial fibrillation. Moreover, in-hospital mortality in patients 
with atherothrombotic infarction was significantly higher in 
the atrial fibrillation group (29.3%) than in the non-atrial 
fibrillation group (18.8%).20 Of note, that atrial fibrilla-
tion was associated with a poorer prognosis both in CI and 
atherothrombotic stroke as compared with stroke patients 
without atrial fibrillation, probably because patients with 
CI showed a higher frequency of congestive heart failure 
and patients with atherothrombotic infarct, a higher rate of 
ischemic heart disease. Chronic atrial fibrillation may cause 
Table 2 Demographic variables, cerebrovascular risk factors, 
neuroimaging findings, and outcome in the first-ever stroke 
according to age (“Sagrat Cor Hospital of Barcelona Stroke 
Registry” for the period 1986–2004)





Age (years), mean (SD) 88.55 (3.2) 70.95 (11.1) 0.0000
Sex 0.0000
 Males 180 (31.2) 1,267 (52.5)
 Females 397 (68.8) 1,146 (47.5)
Hypertension 293 (50.8) 1.344 (55.7) 0.033
Diabetes 88 (15.3) 3,537 (22.3) 0.000
Atrial fibrillation 212 (36.7) 543 (22.5) 0.000
ischemic heart disease 76 (13.2) 341 (14.1) 0.500
Heart failure 60 (10.4) 71 (2.9) 0.000
Heart valve disease 29 (5.0) 146 (6.1) 0.346
TiA 63 (10.9) 282 (11.7) 0.604
Chronic bronchitis 55 (9.5) 177 (7.3) 0.076
Peripheral vascular disease 29 (5.0) 184 (7.6) 0.029
Heavy smoking  
(.20 cigarettes/day)
8 (1.4) 292 (12.1) 0.000
Dyslipidemia 65 (11.3) 498 (20.6) 0.000
Headache 48 (8.3) 415 (17.2) 0.000
Nausea, vomiting 41 (7.1) 246 (10.2) 0.024
Altered consciousness 165 (28.6) 364 (15.1) 0.000
Motor impairment 444 (76.9) 1,658 (68.7) 0.000
Speech disturbance 321 (55.6) 1,185 (49.1) 0.005
Stroke subtypes 0.000
 TiA 79 (13.7) 423 (17.5)
 Atherothrombotic 121 (21.0) 444 (18.4)
 Lacunar 82 (14.2) 484 (20.1)
 Cardioembolic 164 (28.4) 411 (17.0)
 Unknown cause 53 (9.2) 227 (9.4)
 infrequent etiology 4 (0.7) 92 (3.8)
 intracerebral hemorrhage 58 (10.1) 276 (11.4)
 Subarachnoid hemorrhage 5 (0.9) 38 (1.6)
 Subdural hematoma 11 (1.9) 17 (0.7)
 epidural hematoma 0 1 (0.0)
Middle cerebral artery 
topography
266 (46.1) 1,004 (41.6) 0.05
echocardiography 250 (43.3) 1,030 (42.7) 0.779
MRi 72 (12.5) 756 (31.3) 0.000
Neurologic complications 74 (12.5) 236 (9.8) 0.031
Respiratory complications 86 (14.9) 150 (6.2) 0.009
Urinary complications 68 (11.8) 159 (6.6) 0.000
infectious complications 114 (19.8) 241 (10.1) 0.000
Symptom-free at discharge 154 (26.7) 951 (39.4) 0.000
in-hospital death 126 (21.8) 225 (9.3) 0.000
Transfer to convalescent/ 
rehabilitation units
78 (13.5) 238 (9.9) 0.010
Length of stay (days),  
median (interquartile range)
12 (8–20) 11 (7–19) 0.184
Prolonged hospital stay  
.12 days
266 (46.1) 1,030 (42.7) 0.137
Note: Data are expressed as numbers and percentages in parentheses unless 
otherwise stated.
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Current perspectives on cardioembolic ischemic stroke
a significant reduction in cerebral regional blood flow,50,51 
which can be normalized by establishment of sinus rhythm 
after successful cardioversion.
Also, an increase in mortality in CI with atrial fibrillation 
may be explained by the more advanced age of the patients, 
greater size of cerebral infarction, or higher neurological 
deficit at stroke onset.52 In a study of our group,20 the mean 
age of patients with CI and atrial fibrillation was 77.9 years vs 
72.3 years in those without atrial fibrillation. In the group 
of patients with atherothrombotic stroke, mean ages were 
77.4 years in the atrial fibrillation group and 74.9 years in 




In about 80%–95% of cases, symptomatic lacunar strokes are 
caused by microatheromatosis in the proximal segment of a 
penetrating arteriole or by an intracranial branch atheroma-
tous disease.53,54 In contrast, most clinically asymptomatic or 
silent lacunes detected on neuroimaging studies are caused 
by lipohyalinosis of the smallest penetrating arterioles. In the 
remaining 5%–20% of cases, lacunar strokes may be due to 
other etiologies with embolism (of cardiac origin or from a 
complex atheromatosis of the aortic arch) as one of the most 
prevalent of the infrequent causes.55–57
In a clinical series of patients with lacunar infarction, it 
was found that emboligenous cardiopathy as the only cause 
was present in a very small percentage of patients (4%).58 
However, the cardioembolic pathogenetic mechanism may be 
more frequent than apparently expected in very old patients 
($85 years) in whom atrial fibrillation occurs in 28.2% 
of cases vs 8.7% of patients under 85 years old, and has 
been independently associated with cardioembolic lacunar 
stroke.5 Hypertension (61.5% vs 77.3%) and diabetes mel-
litus (7.7% vs 28.4%) were less frequent in very old patients 
with cardioembolic lacunar stroke. In the very elderly, the 
higher occurrence of atrial fibrillation, the lower prevalence of 
hypertension and diabetes, and the greater focal neurological 
impairment (the absence of neurological deficit at discharge, 
15.4% vs 35.2% in patients ,85 years) suggest that the car-
dioembolic mechanism may be more frequent than generally 
established for lacunar infarcts in stroke patients.
In another study,59 diffusion-weighted imaging (DWI) was 
normal in nine out of the 62 patients (14.5%) admitted with a 
classical lacunar syndrome. Forty-two patients (67.7%) had a 
single hyperintense lesion in the territory of deep hemispheric 
or brain stem penetrators. DWI showed multiple regions of 
increased signal intensity in 16% of patients in either a single 
(six patients) or different (four patients) vascular territories, 
strongly indicating an emboligenous stroke mechanism.
Lacunar infarction due to embolism from the aortic arch 
that occurred in two patients with pure motor hemiplegia 
during cardiac and arch angiography has been reported.60 
In a recent study, the possible embolic etiology due to com-
plex atheromatosis of the aortic arch was observed in 3% of 
71 patients with lacunar infarction.61 Two patients in this study 
were 87 years and 91 years old; the first patient presented a 
lacunar infarction in the internal capsule causing pure motor 
hemiparesis, and the second patient had a capsule-ganglionar 
lacunar infarction causing a sensorimotor syndrome. In the 
study of Kazui et al,62 aortic arch atheroma was independently 
associated with an increased risk of lacunar stroke. The find-
ing of multiple acute infarcts by DWI in different vascular 
territories strongly indicates embolism.63–66
Complex atheromatosis  
of the aortic arch
Ultrasonography of the aortic arch allows optimizing the 
diagnosis of complex atheromatosis of the aortic arch, 
which is an emerging etiology of primary or recurrent cere-
bral ischemia, particularly in the subgroup of patients with 
cerebral infarction of unknown cause.67–69 The main criteria 
of the emboligenic risk of aortic plaques include a plaque 
thickness equal to or greater than 4 mm and the presence of 
mobile components inside the plaque.70,71
The association of complex atheromatosis of the aortic 
arch with mitral annular calcification is another interesting 
observation. Mitral annular calcification has been tradition-
ally considered a cerebrovascular risk factor, despite the fact 
that calcium embolism is an exceptional cause of stroke. It 
may be argued that mitral valve ring calcification is an epi-
phenomenon and a marker of complex atheromatosis of the 
aortic arch, with its high emboligenous risk due precisely 
to this association.72 In a clinical series of 121 patients with 
cerebral infarction of undetermined cause, dense mitral 
annular calcification was observed in 58.3% of patients with 
complex atheromatosis of the aortic arch as compared with 
16.3% of patients without complex atheromatosis of the 
aortic arch. Plaques with mobile component (grade III) were 
found in 28% and 9% of patients with and without complex 
atheromatosis of the aortic arch, respectively. Finally, patients 
with complex atheromatosis of the aortic arch in two or more 
of the three zones (ascending aorta, aortic arch, and thoracic 
descending aorta) showed dense mitral annular calcification 
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single area (46% vs 9%). The mean age of patients with dense 
mitral annular calcification was 70.6 years as compared to 
a mean age of 70.5 years for patients without mitral annular 
calcification. Data referring to this clinical situation in very 
old patients are not available.
Paroxysmal atrial fibrillation
The indication of a 24-hour (or longer) Holter monitoring and 
also, in selected cases, transtelephonic monitoring or subcuta-
neous implantation to obtain a prolonged duration of cardiac 
rhythm monitorization allowed to increase the diagnosis of 
rhythm disturbances with a high emboligenous risk, such as 
paroxysmal atrial fibrillation or sinus node disease.73–75
The routine use of transcranial Doppler ultrasound has 
also contributed to improving the diagnosis of right-to-left 
shunt through a patent foramen ovale when bubble signs 
are detected in the middle cerebral artery after injection of 
agitated saline via the antecubital vein.76,77
Both Holter monitoring and transcranial Doppler ultra-
sound are noninvasive diagnostic procedures and can be 
safely performed in the oldest old.
Thrombolytic therapy
At the present time and from the perspective of routine daily 
practice, the indication of vascular repermeabilization with 
the use of intravenous thrombolysis with rt-PA during the 
first 4 1/2 window hours in the acute phase of CI is well 
established. Recommended total dose is 0.9 mg/kg infused 
over 60 minutes (loaded with 10% of the dose). Treatment 
with rt-PA should be administered to patients aged 18 years 
or more, in the presence of a significant neurological 
deficit, computed tomography evidence of the absence of 
intracerebral hemorrhage, or extensive cerebral infarction 
(greater than one third of middle cerebral artery territory), 
and in patients without contraindications for thrombolytic 
therapy.  Treatment with rt-PA should be prescribed by staff 
neurologists and should be administered in hospitals, in 
which patients can be controlled adequately (it is recom-
mended to treat patients with intravenous rt-PA in a stroke 
unit).78–80 However, telemedicine for stroke may be a potential 
solution and may maximize the number of patients given 
effective acute stroke treatment.81 Antithrombotic agents 
(heparin, aspirin) should not be given within 24 hours of 
rt-PA  administration. Before thrombolytic therapy, it is rec-
ommended to reduce blood pressure (BP) if BP levels are 
185/110 mmHg or higher. Also, to be effective, thrombolytic 
therapy should be given as quickly as possible, with higher 
benefits during the first 90 minutes after stroke onset.
Bleeding is the greatest risk of thrombolytic therapy, 
which occurs in 2.3%–6.4% of the patients. Very old age, 
hyperglycemia on admission, greater initial neurological 
deficit, and early signs of cerebral ischemia are predictive 
factors of hemorrhagic complications of intravenous throm-
bolysis.82,83 For this reason, clinical protocols of therapeutic 
indication of intravenous rt-PA should be strictly followed.
In patients with specific contraindications for intrave-
nous thrombolytic therapy, intra-arterial thrombolysis with 
rt-PA by means of an angiography is a potentially beneficial 
treatment. Occlusion of a large artery should be present.84 
In general, in patients with predisposition to hemorrhage, 
intra-arterial thrombolysis is even safer and recommendable 
than intravenous thrombolytic therapy, although mechani-
cal thrombectomy may be another preferable alternative to 
intravenous thrombolysis.85,86 Intra-arterial thrombolysis is a 
therapeutic option in patients with acute ischemic stroke of 
less than 6-hours duration caused by middle cerebral artery 
occlusion. In young patients with acute thrombosis of the 
basilar artery trunk of less than 12-hours duration, intra-
arterial thrombolysis may be considered, given the unfavor-
able prognosis of this type of thrombosis.87
Mechanical thrombectomy is a promising new modality 
of interventional stroke treatment. Thrombectomy devices are 
delivered by endovascular access proximal to the occlusion 
site. Although the experience is limited, an advantage over 
pharmacological thrombolysis is that the risk of bleeding 
is not increased. Indications of mechanical thrombectomy 
are similar to those of intra-arterial thrombolysis, but this 
procedure is particularly recommendable in patients at high 
hemorrhagic risk.85,86,88
Adequate control and treatment of cerebrovascular risk 
factors are needed, preventing hyperglycemia and treating 
hyperthermia during the acute stroke phase, as well as pre-
vention of deep vein thrombosis with low-weight heparin. In 
contrast, statins are not indicated in the treatment of CI.89
Rescue and primary  
endovascular treatment
Rescue endovascular treatment is a strategy that includes the 
use of intravenous thrombolysis followed by intra-arterial 
thrombolysis in cases with no improvement and persistence 
of vascular occlusion. The 6-hour window from the onset of 
clinical symptoms should be maintained for intra-arterial 
thrombolysis, 8 hours for mechanical thrombectomy in 
the anterior cerebral territory, and up to 12 hours in basilar 
artery occlusions because the cerebral territory has a better 
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contraindication for intravenous thrombolysis (eg, patients 
receiving anticoagulation treatment or recent surgery), 
primary endovascular treatment may be recommended. 
However, endovascular treatment requires complex and 
sophisticated health care services and can only be performed 
in specialized and validated reference hospitals (tertiary care 
stroke centers).
New anticoagulants in very  
old patients
Until recently, antivitamin K anticoagulants (acenocoumarol, 
warfarin) were the only drugs available, which have shown 
a clear superiority to aspirin both in primary and secondary 
prevention of cardioembolic events.91,92 Oral anticoagulation 
(INR 2.0–3.0) has been recommended in cerebral ischemic 
infarction associated with atrial fibrillation. Treatment with 
oral anticoagulants is not recommended in patients with 
comorbidities, such as fall risk factors, poor compliance, 
uncontrolled epilepsy, or gastrointestinal bleeding. Advanced 
age by itself does not constitute a contraindication of oral 
anticoagulation.93
Patients with CI unrelated to atrial fibrillation should 
be treated with oral anticoagulants (INR 2.0–3.0) when the 
risk of stroke recurrence is high (eg, mechanical prostheses, 
rheumatic heart disease, myocardial infarction with left 
thrombus formation, left atrial enlargement, or significant 
left ventricular dysfunction).94,95 A combination of a low-
dose aspirin and dipyridamole is recommended when oral 
anticoagulation is contraindicated.
In contrast, oral anticoagulation is routinely recom-
mended in non-CI stroke except in special circumstances 
such as grade III complex atheromatosis of the aortic arch, 
fusiform aneurysms of the basilar artery, central venous 
thrombosis, or CI patients of undetermined cause with a 
patent foramen ovale in the presence of proved deep vein 
thrombosis or associated with atrial septal aneurysm.94,95 
Also, oral anticoagulants can be indicated in patients with 
CI caused by arterial dissection or CI in prothrombotic 
stages secondary to deficiency of protein S, protein C, and 
antithrombin III, lupus anticoagulant deficiency, or resistance 
to activated protein C.
At the present time, three new oral anticoagulants have 
consistently shown a higher safety profile (dabigatran, 
rivaroxaban, and apixaban) and a non-inferior (rivaroxaban) 
or superior (dabigatran 150 mg and apixaban) efficacy as 
compared to coumarin for preventing cardioembolic events in 
patients with non-valvular atrial fibrillation. As an additional 
advantage, these drugs do not need anticoagulant monitor-
ization avoiding periodic hematological controls that are 
indispensable in patients currently treated with antivitamin K 
anticoagulants.96 The pharmacological characteristics of these 
drugs are shown in Table 3.
According to the current recommendations, dabigatran, 
rivaroxaban, and apixaban may be preferred over antivitamin K 
anticoagulants in cerebral ischemic infarction associated with 
non-valvular atrial fibrillation. Clinical decisions should con-
sider risks and benefits of each drug according to individual 
characteristics, including history of previous diseases, risk of 
bleeding, patient’s compliance, and patient’s preferences.97,98 
The experience of the use of these novel anticoagulant drugs 
in very old patients is scarce, but the lack of need for periodic 
monitoring makes these agents potentially interesting and of 
priority use in patients of advanced age.
Future research lines
The evidence that neurogenesis and angiogenesis play a role 
at cerebral level favoring brain neuroplasticity,99 and that they 
are stimulated by movements and exercise of the affected 
hemibody, supports the necessity to maintain an active and 
Table 3 Pharmacological characteristics of new anticoagulant drugs
Dabigatran
 Direct thrombin inhibitor
  Relatively short half-life (12–17 hours), rapid onset of action  
(2–3 hours), few drug interactions, no food interaction
  80% renal elimination; therefore, it should not be used in patients 
with renal failure (creatinine clearance ,15 mL/min)
  Oral route, every 12 hours, and has been shown to be equally 
effective and more safe (less likely to cause hemorrhage) than 
warfarin when given at a dose of 110 mg/12 hours, and more  
effective and equally safe as warfarin when administered at a dose of 
150 mg/12 hours
Rivaroxaban
 Direct factor Xa inhibitor
  Short half-life (5–9 hours), rapid onset of action (2–3 hours), few drug 
interactions, no food interaction
  Low renal elimination (36%), so that it can be administered to 
patients with renal failure. Predictable pharmacokinetics, it can be 
administered at fixed doses, and monitorization of drug levels is not 
required. Similar efficacy as warfarin but more safe
 Oral route at doses of 20 mg/24 hours
Apixaban
 Direct factor Xa inhibitor
 Oral route at doses of 5 mg/12 hours
  Short half-life (8–15 hours), rapid onset of action (3–4 hours), 
predictable pharmacokinetics, it can be administered at fixed doses, 
and monitorization of drug levels is not required
  Low renal elimination (25%), so that it can be administered to patients 
with renal failure without dose modification, contraindicated in the 
presence of creatinine clearance ,15 mL/min
  More effective and safe than warfarin for the prevention of 
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persistent attitude regarding physiotherapy and motor rehabil-
itation, as an indispensable therapeutic approach to improve 
neurological sequelae in cardioembolic stroke patients.
Some clinical research lines remain open, such as 
genetic-related risk of cardioembolism and recurrence,100–103 
diagnosis of embolism based on biomarkers for cases of 
cerebral infarctions of undetermined or unknown etiology, 
and consolidation in daily practice of new oral anticoagulants 
as a more effective, safe, and comfortable therapy.
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